This is an open-label phase 1 study to assess the safety and feasibility of autologous T
cells co-expressing two CARs targeting the cryptic EGFR epitope 806 and IL13Ra2 (referred to
as "CART-EGFR-IL13Ra2 cells") in patients with EGFR-amplified glioblastoma, IDH-wildtype that
has recurred following prior radiotherapy.